Synthesis and characterization of αvβ₃-targeting peptidomimetic chelate conjugates for PET and SPECT imaging.

[1]  Oluwatayo F. Ikotun,et al.  The rise of metal radionuclides in medical imaging: copper-64, zirconium-89 and yttrium-86. , 2011, Future medicinal chemistry.

[2]  B. Pichler,et al.  [68Ga]NODAGA-RGD for imaging αvβ3 integrin expression , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  C. Anderson,et al.  Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. , 2010, Chemical reviews.

[4]  T. Quinn,et al.  203Pb-Labeled α-Melanocyte–Stimulating Hormone Peptide as an Imaging Probe for Melanoma Detection , 2008, Journal of Nuclear Medicine.

[5]  J. Xie,et al.  Radiolabeled high affinity peptidomimetic antagonist selectively targets αvβ3 receptor-positive tumor in mice , 2007 .

[6]  M. Brechbiel,et al.  In vitro and in vivo evaluation of novel ligands for radioimmunotherapy. , 2006, Nuclear medicine and biology.

[7]  Zhimin Shen,et al.  Synthesis, in vitro, and in vivo characterization of an integrin αvβ3-targeted molecular probe for optical imaging of tumor , 2005 .

[8]  M. Brechbiel,et al.  Purification of cyclotron-produced 203Pb for labeling Herceptin. , 2005, Nuclear medicine and biology.

[9]  W. H. Knapp,et al.  68Ga-labelled DOTA-derivatised peptide ligands , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  Junichi Takagi,et al.  Integrin activation and structural rearrangement , 2002, Immunological reviews.

[11]  M. Bednarski,et al.  Tumor Regression by Targeted Gene Delivery to the Neovasculature , 2002, Science.

[12]  Sibylle Ziegler,et al.  Noninvasive Imaging of αvβ3 Integrin Expression Using 18F-labeled RGD-containing Glycopeptide and Positron Emission Tomography , 2001 .

[13]  M Schwaiger,et al.  Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  H. Mäcke,et al.  A convenient synthesis of novel bifunctional prochelators for coupling to bioactive peptides for radiometal labelling. , 2000, Bioorganic & medicinal chemistry letters.

[15]  L. Chappell,et al.  Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb. , 2000, Nuclear medicine and biology.

[16]  M. Brechbiel,et al.  In vivo evaluation of a lead-labeled monoclonal antibody using the DOTA ligand , 1998, European Journal of Nuclear Medicine.

[17]  M. Brechbiel,et al.  Lead(II) complexes of 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetate: solution chemistry and application to tumor localization with 203Pb labeled monoclonal antibodies , 1995 .

[18]  S. Mirzadeh,et al.  The Chemical Fate of 212Bi-DOTA Formed by β- Decay of 212Pb(DOTA)2-*** , 1993 .

[19]  S. Mirzadeh,et al.  Improved in vivo stability and tumor targeting of bismuth-labeled antibody. , 1990, Cancer research.

[20]  Krishan Kumar,et al.  Lead(II) and bismuth(III) complexes of the polyazacycloalkane-N-acetic acids nota, dota, and teta , 1989 .